Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant

H-20068527

The effects of bifidobacterium breve bif195 for small intestinal crohn's disease
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT04842149
Probiotics
Source : Importé depuis le centre
Recrutement fermé
Dernière modification : 2025/05/29
Type de recherche

Interventionnel


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Diagnosed with small intestinal CD
* Fecal calprotectin ≥ 250 ug/g
* IUS evidence of small bowel inflammation with wall thickness ≥ 4 mm
* At least 3 months af stable medical treatment
* Able to read and speak Danish

Exclusion Criteria:

* Positive rectal swab for pathogenic microorganisms
* Use of antibiotics, probiotics and systemic glucocorticosteroids within 4 weeks prior to inclusion
* Participation in other clinical trials within 30 days prior to inclusion
* Pregnancy, planned pregnancy or breast feeding
* Psychiatric disease
* Abuse of alcohol or drugs

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Bif195 capsules The capsule will contain approximately 15\*10\^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule. Donnée non disponible
  • Inconnu
  • Placebo capsules The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule. Donnée non disponible
  • Inconnu
  • Bif195 capsules
    État du recrutement
    unknown
    Placebo capsules
    État du recrutement
    unknown
    Données à jour depuis : 29 mai 2025

    Description de l'étude

    Résumé de l'étude

    The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with small intestinal Crohn's disease.

    Source : Importé depuis le centre

    Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with an incidence rate at 11/100 000 per year in Denmark.

    The disease can potentially affect the entire gastrointestinal tract, though the most common affected area is terminal ileum and the adjacent part of colon.

    CD is a result of both genetic and environmental factors together with the intestinal microbiota, however the precise etiology is unclear.

    A change of the intestinal microbiota with a reduced occurrence of e.g. Bacteroides species, Firmicutes and the anti-inflammatory bacteria Faecalibacterium prausnitzii is found in CD patients compared to healthy controls. Also a reduction of the mucosa-associated Bifidobacteria has been associated with the risk of mucosal inflammation.

    The hypothesis that an imbalance between potentially beneficial and pathogenic bacteria contribute to the pathogenesis of IBD, including CD, has led to the suggestion that manipulation of the microbiota may be an attractive target for therapeutic interventions in IBD.

    A new probiotic bacterium, Bifidobacterium breve Bif195 (Bif195) has been identified and has shown great effects on preventing enteropathy and ulcers on the gut mucosa in healthy volunteers given acetylsalicylic acid (13), and thereby Bif195 has also shown a potential in reducing gut permeability defects. This bacterium has not yet been investigated in CD patients.

    Source : Importé depuis le centre

    Sites

    Centres participants

      1 centres
    • GASTROUNIT, COPENHAGEN UNIVERSITY HOSPITAL HVIDOVRE

      Hvidovre

      COPENHAGEN, DENMARK

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 29 mai 2025
    Données à jour depuis : 31 mai
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT04842149